Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs <i>in vitro</i>
Qi Zhang(Northeast Agricultural University), Yihong Ye(National Institute of Diabetes and Digestive and Kidney Diseases), Catherine Z. Chen(National Institutes of Health), Amy Q. Wang(National Institutes of Health), Manisha Pradhan(National Institutes of Health), Natalie R. Hagen(National Institutes of Health), Wei Zheng(Liaoning Cancer Hospital & Institute), Wenwei Huang(National Institutes of Health), Zhiji Luo(National Institutes of Health), Min Shen(Kaili University), Lu Chen(Chengdu University of Traditional Chinese Medicine), Lihui Wang(Tiangong University), Miao Xu(National Center for Advancing Translational Sciences), Juhyung Lee(National Institute of Diabetes and Digestive and Kidney Diseases), Yue Xu(China Pharmaceutical University), Xin Xu(National Institutes of Health), Manju Swaroop(National Institutes of Health)
Cited by 13
Related Papers
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
|Cell|2020|802
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium
|Cell stem cell|2020|460
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2015|348
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
|Science Translational Medicine|2019|259
Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs
|Emerging Microbes & Infections|2014|242